查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950468

戈蒂埃病酶替代療法市場按產品類型、適應症、分銷管道和患者年齡層分類－全球預測，2026-2032年

Enzyme Replacement Therapy Drugs for Gaucher Disease Market by Product Type, Indication, Distribution Channel, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，高雪氏症酶替代療法市場價值將達到 21.5 億美元，到 2026 年將成長至 25 億美元，到 2032 年將達到 52.5 億美元，複合年成長率為 13.60%。

關鍵市場統計數據
基準年 2025 21.5億美元
預計年份：2026年 25億美元
預測年份 2032 52.5億美元
複合年成長率 (%) 13.60%

本文簡要介紹了高雪氏症酶替代療法在不斷發展的臨床證據、治療模式和支付方期望之間的交會點。

以下介紹將高雪氏症酶替代療法置於現代臨床和商業性環境中，重點闡述了為何當下深入洞察至關重要。生物製藥生產技術的進步、支付方框架的演變以及長期治療效果證據的日益成熟，共同重塑了相關人員的預期。除了療效之外，臨床醫生越來越重視輸注物流和患者的生活品質，而支付方則密切關注療效的相對價值和持久性，這迫使生產者和醫療服務提供者不斷最佳化治療路徑。

製造流程的進步、居家照護的引入以及基於結果的合約如何重新定義酵素替代療法的競爭優勢和臨床決策

酵素替代療法領域正經歷著變革性的轉變，這主要得益於技術進步、以病人為中心的治療模式以及更嚴格的醫保報銷環境。生產技術的進步提高了產品的一致性並降低了某些製程風險，而低溫運輸物流和輸注通訊協定的改進則降低了居家給藥的門檻。這些運作方面的改變促使人們更加關注長期安全性和生活品質（QOL）終點，從而改變了臨床醫生和支付方評估治療價值的方式。

美國關稅帶來的供應鏈壓力和策略影響，以及相關人員如何保障供應連續性並控制准入成本。

美國關稅和貿易政策的調整可能會對罕見疾病酶替代療法的整個供應鏈產生連鎖反應。進口關稅和海關程序的變化可能會使關鍵生物原料、專用耗材和成品藥的採購變得更加複雜，並延長國際運輸前置作業時間。因此，製造商和經銷商可能需要採取措施來降低貿易中斷的風險，例如重新評估籌資策略、增加庫存緩衝或將某些生產過程本地化。

產品、臨床適應症、通路、給藥途徑和患者年齡等方面的具體趨勢將影響治療管理和商業性策略。

細分市場層面的趨勢揭示了產品、適應症、分銷管道、給藥途徑和患者年齡等維度上存在的差異性臨床和商業性影響。酵素替代療法（如伊米苷酶、他利苷酶α和維拉苷酶α）之間的產品差異影響著關於生產過程、免疫抗原性特徵以及與治療相關的服務提供的討論。 1型和3型高雪氏症的適應症特異性考慮因素高雪氏症了不同的臨床終點、監測要求以及對多學科診療的需求，這些都會影響治療通訊協定和與支付方的互動。

區域治療模式、支付方框架和供應鏈策略如何影響美洲、歐洲、中東和非洲以及亞太地區的醫療服務取得和交付方式

區域差異持續影響關鍵地區的臨床實務模式、報銷談判和供應鏈結構。在美洲，成熟的專科醫療網路和深厚的家庭輸液治療傳統，與複雜的支付方環境相結合，需要精細的合約簽訂和循證策略。因此，該地區的相關人員必須在醫療服務模式創新與和支付方密切合作之間取得平衡，以確保患者獲得治療並支持永續的報銷模式。

為什麼臨床證據項目、生產可靠性和綜合患者服務模式是該治療領域公司之間關鍵的差異化因素

在酵素替代療法領域，競爭優勢越來越取決於能否整合臨床可信度、供應保障和以病人為中心的服務模式。主要企業正加大投入，在初步療效試驗之外，進一步挖掘證據，重點關注長期療效、真實世界安全性以及對臨床醫生和支付方至關重要的生活品質指標。同時，各企業正透過強化專業分銷網路、拓展患者支援服務以及投資家庭輸液服務提供者的培訓來提升自身競爭力，從而減少治療依從性的障礙，並改善患者的整體體驗。

領導者應採取切實可行的優先行動，以加強供應韌性，擴大安全居家輸液服務的覆蓋範圍，並將循證項目與基本契約目標相協調。

產業領導者應優先採取一系列切實可行的措施，以增強醫療服務的可及性、降低供應風險並展現其持續的臨床價值。首先，透過多元化採購管道、建立策略性庫存緩衝以及對合作夥伴進行評估，並專注於緊急時應對計畫和可追溯性，來增強價值鏈的韌性。其次，透過投資護理師培訓、數位化遵從性工具和嚴格的安全通訊協定，擴大居家輸液支援服務，使分散式照護成為適合病人的可擴展選擇。

對用於將臨床、營運和政策見解轉化為切實可行的策略制定的證據綜合和專家檢驗方法進行透明描述

本研究整合了同行評審的臨床文獻、監管文件、產品標籤以及公開的採購和供應鏈資訊，以全面了解治療特性和相關人員動態。除一手資料外，本研究還對臨床醫生、專科藥房負責人和供應鏈專業人員進行了專家訪談，以檢驗營運影響並識別實際臨床實踐模式。在適當情況下，本研究也參考了監管指南和安全通告，以支持臨床和生產風險評估。

整合臨床、營運和政策方面的必要因素，以決定酵素替代療法的可近性和療效，以及未來的策略發展路徑。

總之，高雪氏症酶替代療法的關鍵在於臨床療效、營運可行性和支付方合作，這直接決定了患者的治療可近性和長期療效。那些能夠將嚴謹的實證醫學證據、穩健的生產製造和以病人為中心的服務模式結合的機構，將更有能力滿足臨床醫生的期望和支付方的要求。此外，考慮到地區差異和政策環境的不斷變化，靈活且因地制宜的策略可能比一刀切的方法更有效。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 高蒂埃氏症酶替代療法藥物市場（依產品類型分類）

  • 伊米苷酶
  • Taliglucerase alfa
  • Velaglucerase alfa

9. 高蒂埃氏症酶替代療法市場（依適應症分類）

  • 1型高雪氏症
  • III型高雪氏症

10. 高蒂埃病酶替代療法市場（依分銷管道分類）

  • 家庭醫療保健環境
  • 醫院藥房
  • 專科診所

11. 依患者年齡層分類的戈蒂埃氏症酶替代療法藥物市場

  • 成人版
  • 兒童

12. 各地區戈蒂埃病酶替代療法市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 高蒂埃病酶替代療法藥物市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國戈蒂埃病酶替代療法市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國戈蒂埃氏症酶替代療法市場

第16章 中國戈蒂埃病酶替代療法市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amicus Therapeutics, Inc.
  • AvroBio, Inc.
  • BioMarin Pharmaceutical Inc.
  • CANbridge Pharmaceuticals Inc.
  • Chiesi Farmaceutici SpA
  • Eli Lilly and Company
  • Green Cross Corporation
  • JCR Pharmaceuticals Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Protalix BioTherapeutics, Inc.
  • Sanofi SA
  • Spur Therapeutics Limited
  • Sumitomo Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Ultragenyx Pharmaceutical Inc.
Product Code: MRR-4F7A6D4FD882

The Enzyme Replacement Therapy Drugs for Gaucher Disease Market was valued at USD 2.15 billion in 2025 and is projected to grow to USD 2.50 billion in 2026, with a CAGR of 13.60%, reaching USD 5.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.15 billion
Estimated Year [2026] USD 2.50 billion
Forecast Year [2032] USD 5.25 billion
CAGR (%) 13.60%

A concise orienting narrative placing enzyme replacement therapy for Gaucher disease at the intersection of evolving clinical evidence, delivery models, and payer expectations

The following introduction situates enzyme replacement therapies for Gaucher disease within the contemporary clinical and commercial environment, highlighting why focused intelligence matters now. Advances in biologic manufacturing, evolving payer frameworks, and a maturing evidence base for long-term outcomes have together re-shaped stakeholder expectations. Clinicians increasingly weigh infusion logistics and patient quality of life alongside efficacy, while payers scrutinize comparative value and durable outcomes, prompting manufacturers and providers to refine care pathways.

Consequently, senior leaders must reconcile clinical priorities with operational realities. Supply chain resilience, adherence to regulatory standards for biologics, and readiness to support home-based infusion programs have emerged as central strategic imperatives. As the therapeutic landscape continues to move toward individualized care models and value-based arrangements, organizations that combine clinical credibility with nimble commercial execution will be best positioned to influence treatment access and to support patient-centered care goals.

How manufacturing advances, home-care adoption, and outcomes-focused contracting have redefined competitive advantage and clinical decision drivers in enzyme replacement therapies

The landscape for enzyme replacement therapies has undergone transformative shifts driven by technological improvements, patient-centric delivery models, and a more demanding reimbursement environment. Manufacturing advances have improved consistency and reduced certain process risks, while improvements in cold chain logistics and infusion protocols have lowered barriers to home administration. These operational shifts have enabled greater attention to long-term safety and quality-of-life endpoints, which in turn have changed how clinicians and payers assess therapy value.

At the same time, the competitive environment has evolved as new entrants and lifecycle strategies emphasize manufacturing efficiency, differentiated service offerings, and evidence development that extends beyond traditional clinical endpoints. As a result, engagement between manufacturers, specialty pharmacies, and clinical centers has intensified, creating opportunities for novel contracting structures, patient support programs, and data-sharing initiatives that emphasize outcomes and adherence. Together, these shifts are re-defining what constitutes competitive advantage in this therapeutic area.

Strategic implications of tariff-driven supply chain pressures in the United States and how stakeholders can protect continuity and control access costs

Policy adjustments tied to tariffs and trade measures in the United States have the potential to reverberate across supply chains that support enzyme replacement therapies for rare diseases. Changes to import duties or customs protocols can complicate the sourcing of critical biologic starting materials, specialized consumables, and finished drug products, and they can also increase lead times for international shipments. In turn, manufacturers and distributors may need to re-evaluate sourcing strategies, increase inventory buffers, or localize certain production steps to mitigate exposure to trade disruptions.

Beyond logistics, tariff-related cost pressures can influence pricing discussions with payers and may accelerate negotiations around risk-sharing or patient access programs. Providers and specialty pharmacies could face operational impacts if supply continuity is affected, prompting a shift toward diversified supplier networks and stronger contractual protections. Ultimately, proactive scenario planning, heightened visibility into tiered suppliers, and collaborative engagement with regulators and customs authorities will be essential to preserve treatment continuity and to limit downstream effects on patients and care providers.

Segment-specific dynamics across product, clinical indication, distribution channels, administration route, and patient age that determine therapeutic management and commercial approach

Segment-level dynamics reveal differentiated clinical and commercial implications across product, indication, distribution, route, and patient age dimensions. Product-level differentiation among enzyme replacement formulations such as imiglucerase, taliglucerase alfa, and velaglucerase alfa shapes discussion around manufacturing processes, immunogenicity profiles, and service offerings that accompany therapy delivery. Indication-specific considerations between Type 1 Gaucher disease and Type 3 Gaucher disease introduce varying clinical endpoints, monitoring requirements, and multidisciplinary care needs that influence treatment protocols and payer interactions.

Distribution pathways also have distinct operational and patient experience consequences: home healthcare settings emphasize nursing capacity, infusion safety protocols, and remote monitoring, while hospital pharmacies and specialty clinics concentrate on centralized clinical oversight, infusion suite scheduling, and integrated multidisciplinary care. The intravenous infusion route itself drives requirements for infusion infrastructure, trained personnel, and adherence support, which are particularly salient when planning for pediatric versus adult patient management. Patient age group distinctions between adult and pediatric populations further affect dosing strategies, long-term monitoring plans, and caregiver support programs, necessitating tailored value propositions and service models for different segments.

How regional treatment patterns, payer frameworks, and supply chain strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific shape access and delivery approaches

Regional differences continue to shape clinical practice patterns, reimbursement dialogue, and supply chain configurations across major geographies. In the Americas, established specialty care networks and a strong tradition of home-infusion services combine with complex payer landscapes that require nuanced contracting and evidence strategies. Stakeholders in this region must therefore balance innovation in delivery with intensive payer engagement to secure patient access and to support sustainable reimbursement models.

Across Europe, Middle East & Africa, variability in regulatory frameworks and health system funding models leads to heterogeneous adoption timelines and divergent clinical pathways, making localized engagement and real-world evidence collection critical to achieving acceptance. In the Asia-Pacific region, expanding diagnostic capabilities, growing specialty care capacity, and an increasing focus on rare-disease policy are driving rising attention to therapy accessibility, while local manufacturing and regional distribution partnerships offer pathways to improved supply resilience. Taken together, these regional contours underscore the importance of tailored market access and operations strategies that reflect local clinical practice and regulatory nuances.

Why clinical evidence programs, manufacturing reliability, and integrated patient service models are the decisive differentiators among companies operating in this therapeutic area

Competitive positioning in enzyme replacement therapies increasingly rests on integrated capabilities that combine clinical credibility with supply reliability and patient-centered service models. Leading organizations are investing in evidence generation beyond initial efficacy trials, focusing on long-term outcomes, real-world safety, and quality-of-life measures that matter to clinicians and payers. At the same time, firms are differentiating through strengthened specialty distribution networks, enhanced patient support services, and investments in training for home-infusion providers to reduce barriers to treatment adherence and to improve overall patient experience.

Operationally, manufacturing excellence and supply continuity remain core differentiators. Firms that can demonstrate robust process controls, scalable production, and transparent quality systems build greater trust with health systems and payers. Strategic collaborations-ranging from logistics partnerships to value-based contracting pilots-are increasingly employed to align incentives across the ecosystem. In addition, investment in data platforms and post-authorization evidence collection enables firms to substantiate value claims and to adapt service offerings in response to emerging clinical and payer priorities.

Practical priority actions for leaders to strengthen supply resilience, expand safe home-infusion access, and align evidence programs with value-based contracting goals

Industry leaders should prioritize a set of actionable steps to strengthen access, reduce delivery risks, and demonstrate sustained clinical value. First, fortify supply chain resilience through diversified sourcing, strategic inventory buffers, and partner assessments that emphasize contingency planning and traceability. Second, expand support for home-based infusion by investing in nurse training, digital adherence tools, and rigorous safety protocols to make decentralized care a scalable option for appropriate patients.

Third, deepen evidence strategies by generating longitudinal real-world data that captures outcomes meaningful to payers and clinicians, and by aligning clinical endpoints with value-based contracting opportunities. Fourth, pursue collaborative contracting models with payers and providers that share risk and reward while preserving access for patients with the highest clinical need. Finally, engage proactively with regional stakeholders to tailor access initiatives to local regulatory and reimbursement environments, ensuring that implementation plans are sensitive to the operational realities in each jurisdiction.

Transparent explanation of the evidence synthesis and expert validation approach used to align clinical, operational, and policy insights for actionable strategy development

This research synthesizes peer-reviewed clinical literature, regulatory documents, product labeling, and publicly available procurement and supply chain information to construct a comprehensive view of therapy characteristics and stakeholder dynamics. Primary source material was complemented by expert interviews with clinicians, specialty pharmacy leaders, and supply chain professionals to validate operational implications and to illuminate real-world care patterns. Where appropriate, regulatory guidance and safety communications were referenced to ground clinical and manufacturing risk assessments.

Analytical methods emphasized cross-validation between clinical evidence and operational realities, and findings were stress-tested through scenario analysis focused on supply disruption, reimbursement shifts, and changes in care-delivery models. The approach sought to balance depth of clinical understanding with practical consideration of distribution, infusion logistics, and payer engagement, enabling the development of strategic recommendations that are both evidence-based and implementable within typical organizational constraints.

Synthesis of clinical, operational, and policy imperatives that determine access and outcomes for enzyme replacement therapies and strategic pathways forward

In closing, enzyme replacement therapies for Gaucher disease occupy a space where clinical effectiveness, operational execution, and payer alignment converge to determine patient access and long-term outcomes. Organizations that combine rigorous evidence generation with resilient manufacturing and patient-centered delivery models will be positioned to meet clinician expectations and payer demands. Moreover, regional nuances and evolving policy landscapes mean that flexible, localized strategies will outperform one-size-fits-all approaches.

Leaders should therefore integrate scenario planning into their strategic playbooks, invest in partnerships that strengthen both supply and care delivery, and commit to ongoing evidence collection that demonstrates real-world value. By doing so, stakeholders can better support patients and providers, protect continuity of care amid external shocks, and create commercially sustainable paths forward for these critical therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enzyme Replacement Therapy Drugs for Gaucher Disease Market, by Product Type

  • 8.1. Imiglucerase
  • 8.2. Taliglucerase Alfa
  • 8.3. Velaglucerase Alfa

9. Enzyme Replacement Therapy Drugs for Gaucher Disease Market, by Indication

  • 9.1. Type 1 Gaucher Disease
  • 9.2. Type 3 Gaucher Disease

10. Enzyme Replacement Therapy Drugs for Gaucher Disease Market, by Distribution Channel

  • 10.1. Home Healthcare Setting
  • 10.2. Hospital Pharmacy
  • 10.3. Specialty Clinic

11. Enzyme Replacement Therapy Drugs for Gaucher Disease Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Pediatric

12. Enzyme Replacement Therapy Drugs for Gaucher Disease Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Enzyme Replacement Therapy Drugs for Gaucher Disease Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Enzyme Replacement Therapy Drugs for Gaucher Disease Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Enzyme Replacement Therapy Drugs for Gaucher Disease Market

16. China Enzyme Replacement Therapy Drugs for Gaucher Disease Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Alexion Pharmaceuticals, Inc.
  • 17.7. Amicus Therapeutics, Inc.
  • 17.8. AvroBio, Inc.
  • 17.9. BioMarin Pharmaceutical Inc.
  • 17.10. CANbridge Pharmaceuticals Inc.
  • 17.11. Chiesi Farmaceutici S.p.A.
  • 17.12. Eli Lilly and Company
  • 17.13. Green Cross Corporation
  • 17.14. JCR Pharmaceuticals Co., Ltd.
  • 17.15. Johnson & Johnson Services, Inc.
  • 17.16. Pfizer Inc.
  • 17.17. Protalix BioTherapeutics, Inc.
  • 17.18. Sanofi S.A.
  • 17.19. Spur Therapeutics Limited
  • 17.20. Sumitomo Pharma Co., Ltd.
  • 17.21. Takeda Pharmaceutical Company Limited
  • 17.22. Ultragenyx Pharmaceutical Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY IMIGLUCERASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY IMIGLUCERASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY IMIGLUCERASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY TALIGLUCERASE ALFA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY TALIGLUCERASE ALFA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY TALIGLUCERASE ALFA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY VELAGLUCERASE ALFA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY VELAGLUCERASE ALFA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY VELAGLUCERASE ALFA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY TYPE 1 GAUCHER DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY TYPE 1 GAUCHER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY TYPE 1 GAUCHER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY TYPE 3 GAUCHER DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY TYPE 3 GAUCHER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY TYPE 3 GAUCHER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY HOME HEALTHCARE SETTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY HOME HEALTHCARE SETTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY HOME HEALTHCARE SETTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. MIDDLE EAST ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AFRICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASEAN ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GCC ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GCC ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. GCC ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. GCC ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. GCC ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPEAN UNION ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. BRICS ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. G7 ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. G7 ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. G7 ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. G7 ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. G7 ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. NATO ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NATO ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NATO ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NATO ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. NATO ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. UNITED STATES ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. CHINA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA ENZYME REPLACEMENT THERAPY DRUGS FOR GAUCHER DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)